Q-omics provides the consensus-scored CRB3P1 profile across patient tissues and cancer cell-line models. CRB3P1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CRB3P1 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, CRB3P1 RNA expression shows 12,244 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, and KIRP as cancer lineages where CRB3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRB3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRB3P1 survival associations across molecular data types. CRB3P1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRB3P1 RNA expression–survival associations across cancer types. High CRB3P1 expression shows unfavorable associations in LIHC, TGCT, DLBC, THCA and LUSC, but favorable associations in KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CRB3P1 RNA expression.
This table summarizes CRB3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CRB3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRB3P1 shows lower tumor expression in LUAD, LUSC, BRCA and KIRC and higher tumor expression in KIRP. The KIRP box plot shows higher CRB3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with CRB3P1 in patient tissues and cancer cell lines. In patient samples, CRB3P1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
